| Literature DB >> 26513440 |
Wenchao Zhang1, Linping Wang2, Yafei Chen1, Fang Tang2, Fuzhong Xue3, Chengqi Zhang4.
Abstract
INTRODUCTION: Research suggests that targeting high-risk, nonhypertensive patients for preventive intervention may delay the onset of hypertension. We aimed to develop a biomarker-based risk prediction model for assessing hypertension risk in an urban Han Chinese population.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26513440 PMCID: PMC4663898 DOI: 10.5888/pcd12.150192
Source DB: PubMed Journal: Prev Chronic Dis ISSN: 1545-1151 Impact factor: 2.830
Figure 1Prevalence of hypertension, by age, at baseline, in an urban Han population, China, 2005–2010.
Distribution of Age and the 11 Biomarkers for Participants With and Without Baseline Hypertension, China, 2005–2010
| Variable | Without Baseline Hypertension (n = 69,236) | With Baseline Hypertension (n = 26,478) |
|
|---|---|---|---|
|
Mean (SD) | |||
| Age, y | 41.37 (12.37) | 53.62 (14.24) | <.001 |
| Body mass index, kg/m2 | 24.27 (3.59) | 26.86 (3.49) | <.001 |
| Systolic blood pressure, mmHg | 117.4 (12.53) | 149.2 (16.29) | <.001 |
| Diastolic blood pressure, mmHg | 70.84 (9.24) | 86.30 (12.73) | <.001 |
| Fasting blood-glucose, mmol/L | 5.20 (1.11) | 5.80 (1.60) | <.001 |
| Triglycerides, mmol/L | 1.49 (1.32) | 2.06 (1.79) | <.001 |
| High-density lipoprotein cholesterol, mmol/L | 1.33 (0.33) | 1.30 (0.36) | <.001 |
| Hemoglobin, g/L | 146.7 (15.51) | 151.1 (14.40) | <.001 |
| Hematocrit, % | 43.61 (4.05) | 44.74 (3.79) | <.001 |
| White blood cell count, 109/L | 6.46 (1.59) | 6.85 (1.68) | <.001 |
| Lymphocyte, 109/L | 2.07 (0.61) | 2.15 (0.71) | <.001 |
| Neutrophil granulocyte, 109/L | 3.84 (1.23) | 4.11 (1.26) | <.001 |
P values were calculated using Student’s t test.
Factor Loadings by Principal Component Analysis With Varimax Rotation on 11 Routine Health Check-up Biomarkers in Hypertension Patients, China, 2005–2010
| Biomarker | Factor | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Men | Women | |||||||||
| Inflam-matory | Blood Viscidity | IR | BP | Fat Resistance | Inflam-matory | Blood Viscidity | BP | IR | Fat Resistance | |
| BMI | 0.0630 | 0.0978 | 0.3681 | 0.1534 | −0.6950 | 0.1000 | 0.0486 | 0.3131 | 0.2556 | −0.6194 |
| SBP | 0.0527 | −0.1677 | −0.0245 | 0.8540 | 0.0113 | 0.0419 | −0.0574 | 0.7988 | 0.1902 | 0.0234 |
| DBP | −0.0003 | 0.3203 | 0.1370 | 0.7064 | −0.0595 | 0.0114 | 0.1837 | 0.7549 | −0.1657 | −0.1249 |
| FBG | 0.0342 | −0.0994 | 0.6782 | 0.0696 | −0.0777 | 0.0785 | 0.0423 | 0.0011 | 0.7670 | −0.0739 |
| TG | 0.0836 | 0.1380 | 0.7850 | −0.0029 | 0.1003 | 0.0807 | 0.0798 | 0.0356 | 0.7250 | −0.0163 |
| HDL-C | −0.0650 | −0.0171 | 0.2468 | 0.0761 | 0.8323 | −0.0431 | −0.0120 | 0.0782 | 0.0574 | 0.8778 |
| Hb | 0.0627 | 0.9574 | 0.0450 | 0.0333 | −0.0550 | 0.0639 | 0.9705 | 0.0542 | 0.0920 | −0.0403 |
| HCT | 0.1242 | 0.9472 | −0.0234 | 0.0332 | −0.0425 | 0.1146 | 0.9651 | 0.0674 | 0.0640 | −0.0138 |
| WBC | 0.9906 | 0.0718 | 0.0431 | 0.0355 | −0.0512 | 0.9872 | 0.0747 | 0.0170 | 0.0626 | −0.0957 |
| LC | 0.6468 | 0.0577 | 0.0850 | −0.0199 | −0.0306 | 0.6524 | 0.0637 | 0.0837 | 0.1971 | 0.0990 |
| NGC | 0.8548 | 0.0544 | 0.0036 | 0.0589 | −0.0454 | 0.8577 | 0.0571 | −0.0277 | −0.0327 | −0.1728 |
| % Variance explained | 0.2354 | 0.1578 | 0.1260 | 0.1060 | 0.0969 | 0.2464 | 0.1558 | 0.1237 | 0.1037 | 0.0951 |
| Cumulative variance | 0.2354 | 0.3932 | 0.5192 | 0.6252 | 0.7221 | 0.2464 | 0.4022 | 0.5259 | 0.6296 | 0.7247 |
Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; Hb, hemoglobin; HCT, hematocrit; HDL-C, high-density lipoprotein cholesterol; IR, insulin resistance; LC, lymphocyte; NGC, neutrophil granulocyte; SBP, systolic blood pressure; TG, triglycerides; WBC, white blood cell count.
Factor loading >0.5.
Figure 2The 5-year risk matrix for risk appraisal of hypertension by sex. Graphs A1 and B1 are absolute risk matrices for men and women, respectively; graphs A2 and B2 are relative absolute risk matrices for men and women, respectively. The dashed lines indicate discrimination criteria of absolute risk for predicting hypertension; the curved lines indicate mean absolute risk in the population. Abbreviation: HSP, hypertension synthetic predictor.
| Age, y | Hypertension Prevalence, % | |
|---|---|---|
| Men | Women | |
| 18 | 17.91 | 2.08 |
| 19 | 10.23 | 0 |
| 20 | 15.44 | 4.92 |
| 21 | 8.6 | 0.69 |
| 22 | 12.02 | 1.78 |
| 23 | 12.46 | 2.65 |
| 24 | 12.54 | 2.91 |
| 25 | 12.46 | 1.27 |
| 26 | 11.47 | 2.29 |
| 27 | 12.91 | 2.2 |
| 28 | 13.09 | 2.44 |
| 29 | 12.45 | 3.09 |
| 30 | 15.51 | 2.2 |
| 31 | 14.29 | 3.05 |
| 32 | 16.94 | 3.04 |
| 33 | 15.5 | 2.93 |
| 34 | 17.29 | 3.17 |
| 35 | 20.71 | 3.74 |
| 36 | 21.73 | 3.7 |
| 37 | 17.62 | 4.38 |
| 38 | 24.19 | 4.66 |
| 39 | 25.43 | 4.06 |
| 40 | 27.93 | 6.99 |
| 41 | 27.77 | 7.32 |
| 42 | 28.43 | 8.98 |
| 43 | 30.2 | 9.79 |
| 44 | 30.46 | 10.73 |
| 45 | 33.55 | 13.02 |
| 46 | 35.34 | 13.72 |
| 47 | 35.13 | 14.55 |
| 48 | 39.21 | 18.88 |
| 49 | 35.91 | 18.22 |
| 50 | 37.45 | 21.62 |
| 51 | 40.97 | 24.39 |
| 52 | 41.46 | 26.11 |
| 53 | 40.85 | 27.83 |
| 54 | 43.43 | 32.16 |
| 55 | 43.27 | 32.58 |
| 56 | 43.24 | 33.78 |
| 57 | 44.41 | 41.92 |
| 58 | 49.64 | 42.96 |
| 59 | 46.72 | 45.53 |
| 60 | 48.8 | 45.95 |
| 61 | 48.34 | 44.26 |
| 62 | 53.5 | 46.58 |
| 63 | 55 | 54.62 |
| 64 | 53.31 | 54.97 |
| 65 | 55.68 | 53.95 |
| 66 | 58.91 | 58.79 |
| 67 | 58.59 | 53.8 |
| 68 | 64.62 | 53.09 |
| 69 | 62.35 | 60.38 |
| 70 | 64.94 | 62.96 |
| 71 | 64.99 | 68.25 |
| 72 | 63.95 | 62.41 |
| 73 | 71.99 | 68.16 |
| 74 | 71.12 | 70.61 |
| 75 | 71.35 | 69.83 |
| 76 | 71.97 | 69.68 |
| 77 | 79.4 | 67.8 |
| 78 | 74.42 | 75.42 |
| 79 | 70.62 | 73.86 |
| 80 | 72.4 | 68.63 |
| 81 | 64.89 | 75.61 |
| 82 | 70.68 | 71.74 |
| 83 | 77.27 | 58.06 |
| 84 | 70.59 | 81.82 |
| 85 | 60 | 68.42 |